KR20240090519A - 시프로플록사신 및 셀레콕시브를 포함하는 조성물 - Google Patents

시프로플록사신 및 셀레콕시브를 포함하는 조성물 Download PDF

Info

Publication number
KR20240090519A
KR20240090519A KR1020247016529A KR20247016529A KR20240090519A KR 20240090519 A KR20240090519 A KR 20240090519A KR 1020247016529 A KR1020247016529 A KR 1020247016529A KR 20247016529 A KR20247016529 A KR 20247016529A KR 20240090519 A KR20240090519 A KR 20240090519A
Authority
KR
South Korea
Prior art keywords
ciprofloxacin
celecoxib
tablet
hours
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247016529A
Other languages
English (en)
Korean (ko)
Inventor
알론 벤 눈
제프리 스터링
오론 야코비-지비
샤론 코펜 베레드
Original Assignee
뉴로센스 테라퓨틱스 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴로센스 테라퓨틱스 엘티디. filed Critical 뉴로센스 테라퓨틱스 엘티디.
Publication of KR20240090519A publication Critical patent/KR20240090519A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020247016529A 2021-10-19 2022-10-18 시프로플록사신 및 셀레콕시브를 포함하는 조성물 Pending KR20240090519A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163257130P 2021-10-19 2021-10-19
US63/257,130 2021-10-19
PCT/IL2022/051096 WO2023067592A1 (en) 2021-10-19 2022-10-18 Compositions comprising ciprofloxacin and celecoxib

Publications (1)

Publication Number Publication Date
KR20240090519A true KR20240090519A (ko) 2024-06-21

Family

ID=85982158

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247016529A Pending KR20240090519A (ko) 2021-10-19 2022-10-18 시프로플록사신 및 셀레콕시브를 포함하는 조성물

Country Status (9)

Country Link
US (1) US12097185B2 (enExample)
EP (1) EP4419099A4 (enExample)
JP (1) JP7857044B2 (enExample)
KR (1) KR20240090519A (enExample)
CN (1) CN118369097A (enExample)
AU (1) AU2022370513B2 (enExample)
CA (1) CA3235348A1 (enExample)
IL (1) IL312274A (enExample)
WO (1) WO2023067592A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
EP3641820B1 (en) * 2017-06-20 2022-12-28 Neurosense Therapeutics Ltd. Compositions comprising an anti-inflammatory drug and a dicer activator for use in the treatment of neuronal diseases
US12527768B2 (en) * 2017-06-20 2026-01-20 Neurosense Therapeutics Ltd. Compositions comprising an anti-inflammatory drug and a dicer activator for use in the treatment of neuronal diseases

Also Published As

Publication number Publication date
US20230120880A1 (en) 2023-04-20
EP4419099A1 (en) 2024-08-28
US12097185B2 (en) 2024-09-24
IL312274A (en) 2024-06-01
CA3235348A1 (en) 2023-04-27
AU2022370513A1 (en) 2024-05-16
CN118369097A (zh) 2024-07-19
EP4419099A4 (en) 2025-09-24
AU2022370513B2 (en) 2025-09-25
JP2024539116A (ja) 2024-10-28
JP7857044B2 (ja) 2026-05-12
WO2023067592A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
US7674479B2 (en) Sustained-release bupropion and bupropion/mecamylamine tablets
EP1441713B1 (en) Modified release tamsulosin tablets
JP5622773B2 (ja) テトラサイクリンの１日１回製剤
RU2376988C2 (ru) Фармацевтические композиции замедленного высвобождения, содержащие аплиндор и его производные
US20020182256A1 (en) Novel oral dosage form for carvedilol
JP2000229888A (ja) マトリックス制御放出デバイス
US20090124702A1 (en) Pharmaceutical Compositions of Metformin
CA2392085A1 (en) Carvedilol methanesulfonate
WO2022177983A1 (en) Pharmaceutical compositions of cabozantinib
WO2005092336A1 (ja) 溶出制御製剤とその製造方法
WO2018106280A1 (en) Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US20070059365A1 (en) Novel formulation of ropinirole
CN101442990A (zh) 消旋卡多曲的新型给药形式
US6531151B1 (en) Composition containing hydroxypropylmethylcellulose and/or ethylcellulose as disintegrants and process for producing it
BG107372A (bg) Препарати със забавено действие на хинолонови антибиотици и метод за получаването им
EP1696889A1 (en) Pharmaceutical compositions of benzimidazole and processes for their preparation
US9192615B2 (en) Method for the treatment of acne and certain dosage forms thereof
WO2009027786A2 (en) Matrix dosage forms of varenicline
JP7857044B2 (ja) シプロフロキサシン及びセレコキシブを含む組成物
US20080260785A1 (en) Paroxetine compositions
WO2008068778A2 (en) Extended release pharmaceutical composition of pramipexole
BR112024007727B1 (pt) Composições que compreendem ciprofloxacina e celecoxibe
HK40113418A (zh) 包含环丙沙星和塞来昔布的组合物
WO2003035043A2 (en) Pharmaceutical formulation comprising more than 15% tamoxifen
KR101428149B1 (ko) 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D16-EXM-PA0302 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D16-exm-PA0302

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701